{"transactions":[{"id":1423,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-02T23:50:12.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.96,"value":39600.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001628280-26-060234","document":"wk-form4_1788393010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000162828026060234/wk-form4_1788393010.xml","form_type":"4"}},{"id":671820,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T21:05:12.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":4.04,"value":1616000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2033270,"source":{"system":"sec-edgar","filing":"0001598549-26-000011","document":"form4-08312026_090809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000011/form4-08312026_090809.xml","form_type":"4"}},{"id":674643,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-26T20:57:40.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":10,"price":4.5,"value":45.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2433270,"source":{"system":"sec-edgar","filing":"0001598549-26-000009","document":"form4-08262026_080835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000009/form4-08262026_080835.xml","form_type":"4"}},{"id":678516,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":32018,"price":4.5,"value":144081.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2433280,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":678515,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":114700,"price":4.54,"value":520738.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2465298,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":678514,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":45147,"price":4.76,"value":214899.72,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.75 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2579998,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":681808,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":21765,"kind":"person","name":"Tardiff Daniel","position":1,"cik":"0002089301","reported_name":"Tardiff Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-20T00:46:05.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":1738,"price":4.76,"value":8272.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the \"ESPP\") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-058107","document":"wk-form4_1787186763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2089301/000162828026058107/wk-form4_1787186763.xml","form_type":"4"}},{"id":695879,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":5,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":6,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-05T21:39:33.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":3179558,"price":1.5299,"value":4864405.7842,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Ventures VII. 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3179558,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3179558},"source":{"system":"sec-edgar","filing":"0001231919-26-000829","document":"form4-08052026_090822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000123191926000829/form4-08052026_090822.xml","form_type":"4"}},{"id":695292,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-05T21:29:25.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":3179558,"price":1.5299,"value":4864405.7842,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Ventures VII. 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":3179558,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3179558},"source":{"system":"sec-edgar","filing":"0001598549-26-000002","document":"form4-08052026_090821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000002/form4-08052026_090821.xml","form_type":"4"}},{"id":695660,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T21:09:27.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":16378,"price":1.65,"value":27023.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":186388,"source":{"system":"sec-edgar","filing":"0001628280-26-053513","document":"wk-form4_1785964164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000162828026053513/wk-form4_1785964164.xml","form_type":"4"}},{"id":695219,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26132,"kind":"person","name":"Maricich Yuri","position":1,"cik":"0001881045","reported_name":"Maricich Yuri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-05T21:08:56.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":6551,"price":1.65,"value":10809.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":12611,"source":{"system":"sec-edgar","filing":"0001628280-26-053512","document":"wk-form4_1785964133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026053512/wk-form4_1785964133.xml","form_type":"4"}},{"id":696003,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-05T21:08:18.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":6551,"price":1.65,"value":10809.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":74428,"source":{"system":"sec-edgar","filing":"0001628280-26-053511","document":"wk-form4_1785964091.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000162828026053511/wk-form4_1785964091.xml","form_type":"4"}},{"id":695920,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-05T21:07:21.000Z","date":"2026-08-03","kind":"purchase","planned":false,"acquired":true,"shares":6551,"price":1.65,"value":10809.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":284968,"source":{"system":"sec-edgar","filing":"0001628280-26-053505","document":"wk-form4_1785964039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000162828026053505/wk-form4_1785964039.xml","form_type":"4"}},{"id":739765,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:16:12.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042862","document":"wk-form4_1781295368.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000162828026042862/wk-form4_1781295368.xml","form_type":"4"}},{"id":739188,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:16:05.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042861","document":"wk-form4_1781295362.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000162828026042861/wk-form4_1781295362.xml","form_type":"4"}},{"id":739458,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38642,"kind":"person","name":"WILLIAMS DOUGLAS E","position":1,"cik":"0001184847","reported_name":"WILLIAMS DOUGLAS E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:16:19.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042863","document":"wk-form4_1781295377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184847/000162828026042863/wk-form4_1781295377.xml","form_type":"4"}},{"id":739422,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38627,"kind":"person","name":"Holtzman Steven H","position":1,"cik":"0001300247","reported_name":"Holtzman Steven H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:15:58.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042860","document":"wk-form4_1781295354.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1300247/000162828026042860/wk-form4_1781295354.xml","form_type":"4"}},{"id":739123,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38523,"kind":"person","name":"Stewart Murray","position":1,"cik":"0001723450","reported_name":"Stewart Murray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:15:50.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042859","document":"wk-form4_1781295346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723450/000162828026042859/wk-form4_1781295346.xml","form_type":"4"}},{"id":739231,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38571,"kind":"person","name":"Nashat Amir","position":1,"cik":"0001575843","reported_name":"Nashat Amir","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:15:42.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042858","document":"wk-form4_1781295340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575843/000162828026042858/wk-form4_1781295340.xml","form_type":"4"}},{"id":817256,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":21765,"kind":"person","name":"Tardiff Daniel","position":1,"cik":"0002089301","reported_name":"Tardiff Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:48:21.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":170000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0002089301-26-000003","document":"wk-form4_1775249299.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2089301/000208930126000003/wk-form4_1775249299.xml","form_type":"4"}},{"id":815483,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26132,"kind":"person","name":"Maricich Yuri","position":1,"cik":"0001881045","reported_name":"Maricich Yuri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:47:38.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":215000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001881045-26-000002","document":"wk-form4_1775249255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000188104526000002/wk-form4_1775249255.xml","form_type":"4"}},{"id":817109,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:47:04.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":215000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0002033333-26-000002","document":"wk-form4_1775249221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000203333326000002/wk-form4_1775249221.xml","form_type":"4"}},{"id":816919,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:46:22.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":580000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":580000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":580000},"source":{"system":"sec-edgar","filing":"0001927058-26-000002","document":"wk-form4_1775249179.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000192705826000002/wk-form4_1775249179.xml","form_type":"4"}},{"id":815849,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":45936,"kind":"person","name":"MacLean Michael F","position":1,"cik":"0001383731","reported_name":"MacLean Michael F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:44:54.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant."}],"balance_after":56000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001383731-26-000006","document":"wk-form4_1775249091.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383731/000138373126000006/wk-form4_1775249091.xml","form_type":"4"}},{"id":961302,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":21765,"kind":"person","name":"Tardiff Daniel","position":1,"cik":"0002089301","reported_name":"Tardiff Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T22:42:07.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":145500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service."}],"balance_after":145500,"derivative":{"exercise_price":6.01,"expiration_date":"2035-12-10","underlying":"Common Stock","underlying_shares":145500},"source":{"system":"sec-edgar","filing":"0002089301-25-000004","document":"wk-form4_1766443325.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2089301/000208930125000004/wk-form4_1766443325.xml","form_type":"4"}},{"id":960594,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26132,"kind":"person","name":"Maricich Yuri","position":1,"cik":"0001881045","reported_name":"Maricich Yuri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T22:41:49.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service."}],"balance_after":190000,"derivative":{"exercise_price":6.01,"expiration_date":"2035-12-10","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001881045-25-000005","document":"wk-form4_1766443306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000188104525000005/wk-form4_1766443306.xml","form_type":"4"}},{"id":961237,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T22:41:33.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service."}],"balance_after":190000,"derivative":{"exercise_price":6.01,"expiration_date":"2035-12-10","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0002033333-25-000005","document":"wk-form4_1766443290.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000203333325000005/wk-form4_1766443290.xml","form_type":"4"}},{"id":961156,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T22:41:14.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service."}],"balance_after":425000,"derivative":{"exercise_price":6.01,"expiration_date":"2035-12-10","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001927058-25-000004","document":"wk-form4_1766443271.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000192705825000004/wk-form4_1766443271.xml","form_type":"4"}},{"id":1040133,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:14:56.000Z","date":"2025-09-11","kind":"grant","planned":false,"acquired":true,"shares":2941176,"price":1.53,"value":4499999.28,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2941176,"source":{"system":"sec-edgar","filing":"0001598549-25-000004","document":"form4-09162025_120953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854925000004/form4-09162025_120953.xml","form_type":"4"}},{"id":1040633,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":5,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":6,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:12:20.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":2941176,"price":1.53,"value":4499999.28,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2941176,"source":{"system":"sec-edgar","filing":"0001231919-25-000196","document":"form4-09152025_100930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000123191925000196/form4-09152025_100930.xml","form_type":"4"}},{"id":1042731,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T20:59:09.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":85468,"price":1.53,"value":130766.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":197661,"source":{"system":"sec-edgar","filing":"0001193125-25-201392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000119312525201392/ownership.xml","form_type":"4"}},{"id":1042730,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T20:59:09.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":1221721,"price":1.53,"value":1869233.13,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2825500,"source":{"system":"sec-edgar","filing":"0001193125-25-201392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000119312525201392/ownership.xml","form_type":"4"}},{"id":1042504,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26132,"kind":"person","name":"Maricich Yuri","position":1,"cik":"0001881045","reported_name":"Maricich Yuri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-11T20:25:23.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6060,"price":1.65,"value":9999.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":6060,"source":{"system":"sec-edgar","filing":"0001881045-25-000003","document":"wk-form4_1757622320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000188104525000003/wk-form4_1757622320.xml","form_type":"4"}},{"id":1043057,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-11T20:24:34.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6060,"price":1.65,"value":9999.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":67877,"source":{"system":"sec-edgar","filing":"0002033333-25-000003","document":"wk-form4_1757622271.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000203333325000003/wk-form4_1757622271.xml","form_type":"4"}},{"id":1043009,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-11T20:23:42.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6060,"price":1.65,"value":9999.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":278417,"source":{"system":"sec-edgar","filing":"0001927058-25-000002","document":"wk-form4_1757622219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000192705825000002/wk-form4_1757622219.xml","form_type":"4"}},{"id":1042794,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T20:22:32.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":15151,"price":1.65,"value":24999.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share."}],"balance_after":170010,"source":{"system":"sec-edgar","filing":"0001490283-25-000003","document":"wk-form4_1757622149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000149028325000003/wk-form4_1757622149.xml","form_type":"4"}},{"id":1042544,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38571,"kind":"person","name":"Nashat Amir","position":1,"cik":"0001575843","reported_name":"Nashat Amir","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T16:48:30.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":85468,"price":1.53,"value":130766.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members, including the Reporting Person, or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":197661,"source":{"system":"sec-edgar","filing":"0001193125-25-201380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575843/000119312525201380/ownership.xml","form_type":"4"}},{"id":1042543,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38571,"kind":"person","name":"Nashat Amir","position":1,"cik":"0001575843","reported_name":"Nashat Amir","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T16:48:30.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":1221721,"price":1.53,"value":1869233.13,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, the Reporting Person, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2825500,"source":{"system":"sec-edgar","filing":"0001193125-25-201380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575843/000119312525201380/ownership.xml","form_type":"4"}},{"id":1099870,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:03:21.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000061","document":"wk-form4_1751054595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000061/wk-form4_1751054595.xml","form_type":"4"}},{"id":1100161,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:03:11.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000060","document":"wk-form4_1751054585.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000173673025000060/wk-form4_1751054585.xml","form_type":"4"}},{"id":1100159,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":39266,"kind":"person","name":"Higgins Michael J","position":1,"cik":"0001478521","reported_name":"Higgins Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:03:01.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000059","document":"wk-form4_1751054575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478521/000173673025000059/wk-form4_1751054575.xml","form_type":"4"}},{"id":1099906,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:02:54.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000058","document":"wk-form4_1751054565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000173673025000058/wk-form4_1751054565.xml","form_type":"4"}},{"id":1099869,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:02:10.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000054","document":"wk-form4_1751054523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000054/wk-form4_1751054523.xml","form_type":"4"}},{"id":1100035,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38627,"kind":"person","name":"Holtzman Steven H","position":1,"cik":"0001300247","reported_name":"Holtzman Steven H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T16:02:41.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000057","document":"wk-form4_1751054555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1300247/000173673025000057/wk-form4_1751054555.xml","form_type":"4"}},{"id":1099914,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38571,"kind":"person","name":"Nashat Amir","position":1,"cik":"0001575843","reported_name":"Nashat Amir","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T16:02:31.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000056","document":"wk-form4_1751054544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575843/000173673025000056/wk-form4_1751054544.xml","form_type":"4"}},{"id":1100508,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":78060,"kind":"person","name":"Thadhani Ravi I.","position":1,"cik":"0002032665","reported_name":"Thadhani Ravi I.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T16:02:20.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000055","document":"wk-form4_1751054534.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032665/000173673025000055/wk-form4_1751054534.xml","form_type":"4"}},{"id":1178649,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26132,"kind":"person","name":"Maricich Yuri","position":1,"cik":"0001881045","reported_name":"Maricich Yuri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T20:08:11.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":80000,"derivative":{"exercise_price":3.86,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001628280-25-016484","document":"wk-form4_1743710881.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828025016484/wk-form4_1743710881.xml","form_type":"4"}},{"id":1180320,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T20:07:07.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":80000,"derivative":{"exercise_price":3.86,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001628280-25-016482","document":"wk-form4_1743710820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000162828025016482/wk-form4_1743710820.xml","form_type":"4"}},{"id":1180159,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T20:06:02.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":160000,"derivative":{"exercise_price":3.86,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001628280-25-016481","document":"wk-form4_1743710748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000162828025016481/wk-form4_1743710748.xml","form_type":"4"}},{"id":1180321,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":81142,"kind":"person","name":"Bumcrot David","position":1,"cik":"0002033326","reported_name":"Bumcrot David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T16:09:40.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant."}],"balance_after":45000,"derivative":{"exercise_price":3.86,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001628280-25-016486","document":"wk-form4_1743710973.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033326/000162828025016486/wk-form4_1743710973.xml","form_type":"4"}},{"id":1196889,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38642,"kind":"person","name":"WILLIAMS DOUGLAS E","position":1,"cik":"0001184847","reported_name":"WILLIAMS DOUGLAS E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-19T16:09:30.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":17787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant."}],"balance_after":17787,"derivative":{"exercise_price":5.37,"expiration_date":"2035-03-16","underlying":"Common Stock","underlying_shares":17787},"source":{"system":"sec-edgar","filing":"0001736730-25-000012","document":"wk-form4_1742414964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184847/000173673025000012/wk-form4_1742414964.xml","form_type":"4"}},{"id":1196671,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":38523,"kind":"person","name":"Stewart Murray","position":1,"cik":"0001723450","reported_name":"Stewart Murray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-19T16:07:33.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":17787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant."}],"balance_after":17787,"derivative":{"exercise_price":5.37,"expiration_date":"2035-03-16","underlying":"Common Stock","underlying_shares":17787},"source":{"system":"sec-edgar","filing":"0001736730-25-000011","document":"wk-form4_1742414847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723450/000173673025000011/wk-form4_1742414847.xml","form_type":"4"}},{"id":1382865,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":277536,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382864,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3967234,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":353718},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382863,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":980829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":87448},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382862,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":14020475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250061},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382861,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reported securities are owned directly by Polaris Partners X, L.P. (\"PP X\"). Polaris Partners GP X, L.L.C. (\"PPGP X\") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the \"PPGP X Managing Members\"). Amir Nashat (\"Mr. Nashat\"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X.  Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":909090,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382860,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":24745,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":112193,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382859,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":353718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1603779,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382858,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":87448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":87448,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382857,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1250061,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1250061,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1385074,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":679163,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":60554},"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385073,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15001312,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337513},"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385072,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":545454,"price":11,"value":5999994.0,"ownership":{"direct":false,"nature":"By AH Bio Fund IV, L.P., as nominee"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by AH Bio Fund IV, L.P. (\"AH Bio IV\"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP (collectively, the \"AH Bio Fund IV Entities\"). AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\"), the general partner of AH Bio IV, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio IV, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio IV and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":545454,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385071,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":181818,"price":11,"value":1999998.0,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":1579885,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1385070,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86743,"kind":"organization","name":"AH Equity Partners Bio I, L.L.C.","position":1,"cik":"0001656626","reported_name":"AH Equity Partners Bio I, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86744,"kind":"organization","name":"AH Bio Fund I, L.P.","position":2,"cik":"0001656629","reported_name":"AH Bio Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24716,"kind":"organization","name":"AH Equity Partners Bio IV, L.L.C.","position":3,"cik":"0001889898","reported_name":"AH Equity Partners Bio IV, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24715,"kind":"organization","name":"AH Bio Fund IV, L.P.","position":4,"cik":"0001889476","reported_name":"AH Bio Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T21:05:20.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1398067,"ownership":{"direct":false,"nature":"By AH Bio Fund I, L.P., as nominee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by AH Bio Fund I, L.P. (\"AH Bio I\") for itself and as nominee for AH Bio Fund I-B, L.P.  AH Equity Partners Bio I, L.L.C. (\"AH EP Bio I\"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims\nthe existence of a \"group\" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest\ntherein, if any."}],"balance_after":1398067,"source":{"system":"sec-edgar","filing":"0001415889-24-025380","document":"form4-10172024_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000141588924025380/form4-10172024_091016.xml","form_type":"4"}},{"id":1384928,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":5287303,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":471415},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384927,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":11251624,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1003193},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384926,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":763636,"price":11,"value":8399996.0,"ownership":{"direct":false,"nature":"By Northpond Ventures III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Northpond Ventures III, LP (\"Northpond Fund III\").  Northpond Ventures III GP, LLC (\"Northpond III GP\") is the general partner of Northpond Fund III, and Michael P. Rubin is the managing member of Northpond III GP. As a result, each of Northpond III GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":763636,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384925,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":471415,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":471415,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384924,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1003193,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1003193,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1385043,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86734,"kind":"organization","name":"ENAVATE SCIENCES GP, LLC","position":1,"cik":"0001953107","reported_name":"Enavate Sciences GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86735,"kind":"organization","name":"Everest Aggregator, LP","position":2,"cik":"0002040426","reported_name":"Everest Aggregator, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T16:15:05.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":27166530,"ownership":{"direct":false,"nature":"By Everest Aggregator, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by Everest Aggregator, LP (\"Everest\"). Enavate Sciences GP, LLC (\"Enavate\") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2422166},"source":{"system":"sec-edgar","filing":"0001415889-24-025354","document":"form4-10172024_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040426/000141588924025354/form4-10172024_041001.xml","form_type":"4"}},{"id":1385042,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86734,"kind":"organization","name":"ENAVATE SCIENCES GP, LLC","position":1,"cik":"0001953107","reported_name":"Enavate Sciences GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86735,"kind":"organization","name":"Everest Aggregator, LP","position":2,"cik":"0002040426","reported_name":"Everest Aggregator, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T16:15:05.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":1363636,"price":11,"value":14999996.0,"ownership":{"direct":false,"nature":"By Everest Aggregator, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by Everest Aggregator, LP (\"Everest\"). Enavate Sciences GP, LLC (\"Enavate\") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3785802,"source":{"system":"sec-edgar","filing":"0001415889-24-025354","document":"form4-10172024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040426/000141588924025354/form4-10172024_041001.xml","form_type":"4"}},{"id":1385041,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86734,"kind":"organization","name":"ENAVATE SCIENCES GP, LLC","position":1,"cik":"0001953107","reported_name":"Enavate Sciences GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86735,"kind":"organization","name":"Everest Aggregator, LP","position":2,"cik":"0002040426","reported_name":"Everest Aggregator, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T16:15:05.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":2422166,"ownership":{"direct":false,"nature":"By Everest Aggregator, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by Everest Aggregator, LP (\"Everest\"). Enavate Sciences GP, LLC (\"Enavate\") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2422166,"source":{"system":"sec-edgar","filing":"0001415889-24-025354","document":"form4-10172024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040426/000141588924025354/form4-10172024_041001.xml","form_type":"4"}},{"id":1386643,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":277536,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386642,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3967234,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":353718},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386641,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":980829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":87448},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386640,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":14020475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250061},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386639,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reported securities are owned directly by Polaris Partners X, L.P. (\"PP X\"). Polaris Partners GP X, L.L.C. (\"PPGP X\") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the \"PPGP X Managing Members\"). Amir Nashat (\"Mr. Nashat\"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X.  Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":909090,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386638,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":24745,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":112193,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386637,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":353718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1603779,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386636,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":87448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":87448,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386635,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1250061,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1250061,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386765,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3395816,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302770},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386764,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":4244770,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":378463},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386763,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15002166,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337592},"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386762,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2625145,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386761,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":302770,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP and Dr. Parmar disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":302770,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386760,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:56:35.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1716055,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1716055,"source":{"system":"sec-edgar","filing":"0001415889-24-025140","document":"form4-10152024_091031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924025140/form4-10152024_091031.xml","form_type":"4"}},{"id":1386484,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3395816,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by 5AM Opportunities II, L.P. (\"5AM Opportunities\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of 5AM Opportunities. The Reporting Person is a managing member of Opportunities II GP and may be deemed to share voting and investment power over the shares held by 5AM Opportunities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302770},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386483,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":4244770,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":378463},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386482,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15002166,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337592},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386481,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2625145,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386480,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":302770,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by 5AM Opportunities II, L.P. (\"5AM Opportunities\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of 5AM Opportunities. The Reporting Person is a managing member of Opportunities II GP and may be deemed to share voting and investment power over the shares held by 5AM Opportunities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":302770,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386479,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":378463,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":1716055,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386478,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1337592,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":1337592,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386665,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T21:46:10.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":100014,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8917},"source":{"system":"sec-edgar","filing":"0001104659-24-108700","document":"tm2426125-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000110465924108700/tm2426125-2_4seq1.xml","form_type":"4"}},{"id":1386664,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26224,"kind":"person","name":"Young Richard A","position":1,"cik":"0001490283","reported_name":"Young Richard A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:46:10.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":8917,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering."}],"balance_after":154859,"source":{"system":"sec-edgar","filing":"0001104659-24-108700","document":"tm2426125-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1490283/000110465924108700/tm2426125-2_4seq1.xml","form_type":"4"}},{"id":1386780,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:45:11.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":6791,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":605},"source":{"system":"sec-edgar","filing":"0001104659-24-108699","document":"tm2426125-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000110465924108699/tm2426125-1_4seq1.xml","form_type":"4"}},{"id":1386779,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-15T21:45:11.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering."}],"balance_after":272357,"source":{"system":"sec-edgar","filing":"0001104659-24-108699","document":"tm2426125-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000110465924108699/tm2426125-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2024-10-15T21:45:11.000000Z,1386779"}